Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
24 mai 2024 08h01 HE
|
Perspective Therapeutics, Inc.
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
20 mai 2024 07h00 HE
|
Perspective Therapeutics, Inc.
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
15 mai 2024 07h00 HE
|
Perspective Therapeutics, Inc.
Continued progress enrolling in its VMT-α-NET and VMT01 clinical trialsDisclosed a new internally discovered molecule that targets fibroblast activation protein-αAnnounced the in-licensing of a...
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
03 mai 2024 07h00 HE
|
Perspective Therapeutics, Inc.
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
02 mai 2024 07h00 HE
|
Perspective Therapeutics, Inc.
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
30 avr. 2024 07h00 HE
|
Perspective Therapeutics, Inc.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
08 avr. 2024 08h00 HE
|
Perspective Therapeutics, Inc.
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
28 mars 2024 07h30 HE
|
Perspective Therapeutics, Inc.
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
18 mars 2024 08h00 HE
|
Perspective Therapeutics, Inc.
SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
11 mars 2024 08h00 HE
|
Perspective Therapeutics, Inc.
SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...